160 related articles for article (PubMed ID: 26803606)
1. Beta-amyloid and phosphorylated tau metabolism changes in narcolepsy over time.
Liguori C; Placidi F; Izzi F; Nuccetelli M; Bernardini S; Sarpa MG; Cum F; Marciani MG; Mercuri NB; Romigi A
Sleep Breath; 2016 Mar; 20(1):277-83; discussion 283. PubMed ID: 26803606
[TBL] [Abstract][Full Text] [Related]
2. CSF beta-amyloid levels are altered in narcolepsy: a link with the inflammatory hypothesis?
Liguori C; Placidi F; Albanese M; Nuccetelli M; Izzi F; Marciani MG; Mercuri NB; Bernardini S; Romigi A
J Sleep Res; 2014 Aug; 23(4):420-4. PubMed ID: 24635662
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal Fluid Biomarkers of Neurodegeneration Are Decreased or Normal in Narcolepsy.
Jennum PJ; Østergaard Pedersen L; Czarna Bahl JM; Modvig S; Fog K; Holm A; Rahbek Kornum B; Gammeltoft S
Sleep; 2017 Jan; 40(1):. PubMed ID: 28364448
[TBL] [Abstract][Full Text] [Related]
4. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
5. Obstructive sleep apnea may induce orexinergic system and cerebral β-amyloid metabolism dysregulation: is it a further proof for Alzheimer's disease risk?
Liguori C; Mercuri NB; Nuccetelli M; Izzi F; Cordella A; Bernardini S; Placidi F
Sleep Med; 2019 Apr; 56():171-176. PubMed ID: 30799255
[TBL] [Abstract][Full Text] [Related]
6. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease.
Sunderland T; Linker G; Mirza N; Putnam KT; Friedman DL; Kimmel LH; Bergeson J; Manetti GJ; Zimmermann M; Tang B; Bartko JJ; Cohen RM
JAMA; 2003 Apr 23-30; 289(16):2094-103. PubMed ID: 12709467
[TBL] [Abstract][Full Text] [Related]
7. Increased cerebrospinal fluid levels of nerve cell biomarkers in narcolepsy with cataplexy.
Heier MS; Skinningsrud A; Paus E; Gautvik KM
Sleep Med; 2014 Jun; 15(6):614-8. PubMed ID: 24784789
[TBL] [Abstract][Full Text] [Related]
8. Additional use of Aβ₄₂/Aβ₄₀ ratio with cerebrospinal fluid biomarkers P-tau and Aβ₄₂ increases the level of evidence of Alzheimer's disease pathophysiological process in routine practice.
Sauvée M; DidierLaurent G; Latarche C; Escanyé MC; Olivier JL; Malaplate-Armand C
J Alzheimers Dis; 2014; 41(2):377-86. PubMed ID: 24614902
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid biomarkers distinguish postmortem-confirmed Alzheimer's disease from other dementias and healthy controls in the OPTIMA cohort.
Seeburger JL; Holder DJ; Combrinck M; Joachim C; Laterza O; Tanen M; Dallob A; Chappell D; Snyder K; Flynn M; Simon A; Modur V; Potter WZ; Wilcock G; Savage MJ; Smith AD
J Alzheimers Dis; 2015; 44(2):525-39. PubMed ID: 25391385
[TBL] [Abstract][Full Text] [Related]
10. Cerebrospinal fluid biomarkers of neurodegeneration in patients with juvenile and classic myotonic dystrophy type 1.
Peric S; Mandic-Stojmenovic G; Markovic I; Stefanova E; Ilic V; Parojcic A; Misirlic-Dencic S; Ostojic M; Rakocevic-Stojanovic V; Kostic V
Eur J Neurol; 2014 Feb; 21(2):231-7. PubMed ID: 23834502
[TBL] [Abstract][Full Text] [Related]
11. Cystatin C levels are positively correlated with both Abeta42 and tau levels in cerebrospinal fluid in persons with Alzheimer's disease, mild cognitive impairment, and healthy controls.
Sundelöf J; Sundström J; Hansson O; Eriksdotter-Jönhagen M; Giedraitis V; Larsson A; Degerman-Gunnarsson M; Ingelsson M; Minthon L; Blennow K; Kilander L; Basun H; Lannfelt L
J Alzheimers Dis; 2010; 21(2):471-8. PubMed ID: 20555147
[TBL] [Abstract][Full Text] [Related]
12. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.
Mattsson N; Zetterberg H; Hansson O; Andreasen N; Parnetti L; Jonsson M; Herukka SK; van der Flier WM; Blankenstein MA; Ewers M; Rich K; Kaiser E; Verbeek M; Tsolaki M; Mulugeta E; Rosén E; Aarsland D; Visser PJ; Schröder J; Marcusson J; de Leon M; Hampel H; Scheltens P; Pirttilä T; Wallin A; Jönhagen ME; Minthon L; Winblad B; Blennow K
JAMA; 2009 Jul; 302(4):385-93. PubMed ID: 19622817
[TBL] [Abstract][Full Text] [Related]
13. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
15. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study.
Hansson O; Zetterberg H; Buchhave P; Londos E; Blennow K; Minthon L
Lancet Neurol; 2006 Mar; 5(3):228-34. PubMed ID: 16488378
[TBL] [Abstract][Full Text] [Related]
16. Orexin-A is Associated with Increases in Cerebrospinal Fluid Phosphorylated-Tau in Cognitively Normal Elderly Subjects.
Osorio RS; Ducca EL; Wohlleber ME; Tanzi EB; Gumb T; Twumasi A; Tweardy S; Lewis C; Fischer E; Koushyk V; Cuartero-Toledo M; Sheikh MO; Pirraglia E; Zetterberg H; Blennow K; Lu SE; Mosconi L; Glodzik L; Schuetz S; Varga AW; Ayappa I; Rapoport DM; de Leon MJ
Sleep; 2016 Jun; 39(6):1253-60. PubMed ID: 26951396
[TBL] [Abstract][Full Text] [Related]
17. Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.
Thaweepoksomboon J; Senanarong V; Poungvarin N; Chakorn T; Siwasariyanon N; Washirutmangkur L; Udompunthuruk S
J Med Assoc Thai; 2011 Feb; 94 Suppl 1():S77-83. PubMed ID: 21721431
[TBL] [Abstract][Full Text] [Related]
18. CSF biomarkers for Alzheimer disease correlate with cortical brain biopsy findings.
Seppälä TT; Nerg O; Koivisto AM; Rummukainen J; Puli L; Zetterberg H; Pyykkö OT; Helisalmi S; Alafuzoff I; Hiltunen M; Jääskeläinen JE; Rinne J; Soininen H; Leinonen V; Herukka SK
Neurology; 2012 May; 78(20):1568-75. PubMed ID: 22517093
[TBL] [Abstract][Full Text] [Related]
19. CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.
Wallin AK; Blennow K; Andreasen N; Minthon L
Dement Geriatr Cogn Disord; 2006; 21(3):131-8. PubMed ID: 16391474
[TBL] [Abstract][Full Text] [Related]
20. Slowing of EEG correlates with CSF biomarkers and reduced cognitive speed in elderly with normal cognition over 4 years.
Stomrud E; Hansson O; Minthon L; Blennow K; Rosén I; Londos E
Neurobiol Aging; 2010 Feb; 31(2):215-23. PubMed ID: 18462837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
